RxDoctor Payments Data

Barbara Yosaitis, MD

Internal Medicine · Fairfax, VANPI 1679617997

Payments from drug & device makers

$7,170in general payments, 2019–2025

Across 383 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$950
  • Amgen$669
  • Boehringer Ingelheim$484
  • AstraZeneca$329
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$7,156100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,170 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$225,852
Medicare patients
338
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$55,197
JardianceEmpagliflozin27$35,311
OzempicSemaglutide31$29,978
ViberziEluxadoline12$19,860
JanuviaSitagliptin Phosphate14$17,258
WegovySemaglutide11$14,196
RybelsusSemaglutide14$14,184
SynthroidLevothyroxine Sodium80$6,967
Breo ElliptaFluticasone/Vilanterol12$6,231
TegretolCarbamazepine11$5,833
Atorvastatin Calcium361$3,486
Candesartan Cilexetil32$3,015
Metoprolol Succinate111$1,745
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$1,561
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$1,287$58,35756 claims
PfizerEliquis, Paxlovid$950$56,56555 claims
Boehringer IngelheimJardiance$484$35,31127 claims
AbbVieViberzi, Synthroid$1,195$26,82892 claims
MerckJanuvia$105$17,25814 claims
GSKBreo Ellipta$23$6,23112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →